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Xeroderma Pigmentosum-Variant Patients from
America, Europe, and Asia
Hiroki Inui1,15, Kyu-Seon Oh1,15, Carine Nadem1, Takahiro Ueda1, Sikandar G. Khan1, Ahmet Metin2,
Engin Gozukara3, Steffen Emmert4, Hanoch Slor5, David B. Busch{,6, Carl C. Baker7, John J. DiGiovanna1,8,
Deborah Tamura1, Cornelia S. Seitz9, Alexei Gratchev10, Wen Hao Wu11, Kee Yang Chung11,
Hye Jin Chung11, Esther Azizi12, Roger Woodgate13, Thomas D. Schneider14 and Kenneth H. Kraemer1
Xeroderma pigmentosum-variant (XP-V) patients have sun sensitivity and increased skin cancer risk. Their cells
have normal nucleotide excision repair, but have defects in the POLH gene encoding an error-prone
polymerase, DNA polymeraseZ (polZ). To survey the molecular basis of XP-V worldwide, we measured polZ
protein in skin fibroblasts from putative XP-V patients (aged 8–66 years) from 10 families in North America,
Turkey, Israel, Germany, and Korea. PolZ was undetectable in cells from patients in eight families, whereas two
showed faint bands. DNA sequencing identified 10 different POLH mutations. There were two splicing, one
nonsense, five frameshift (3 deletion and 2 insertion), and two missense mutations. Nine of these mutations
involved the catalytic domain. Although affected siblings had similar clinical features, the relation between the
clinical features and the mutations was not clear. POLH mRNA levels were normal or reduced by 50% in three
cell strains with undetectable levels of polZ protein, indicating that nonsense-mediated message decay was
limited. We found a wide spectrum of mutations in the POLH gene among XP-V patients in different countries,
suggesting that many of these mutations arose independently.
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INTRODUCTION
To maintain DNA integrity, cells have multiple pathways to
repair DNA damage caused by environmental agents. The
failure of these systems leads to human disease. Xeroderma
pigmentosum (XP) is an autosomal recessive disorder with an
extremely high sensitivity to UV radiation, leading to a 1,000-
fold increase in the incidence of sunlight-induced skin
cancer, caused by defective DNA repair (Kraemer et al.,
1987, 1994, 2007; Bootsma et al., 2002; Kraemer, 2003;
Friedberg et al., 2006).
Genetic studies on cultured cells from XP patients
revealed seven complementation groups, XP-A through XP-
G, as well as a variant (XP-V) (OMIM no. 278750). The cells
from XP-A through XP-G are defective in nucleotide-excision
repair, which is responsible for the removal of UV-induced
damage in genomic DNA (Van Steeg and Kraemer, 1999;
Friedberg et al., 2006). Although different complementation
groups exhibit diverse clinical features, these XP patients
generally have early onset of skin cancers and about 20%
(XP-A, XP-B, XP-G, and XP-D) exhibit neurological abnorm-
alities (Rapin et al., 2000; Kraemer, 2003; Kraemer et al.,
2007). In contrast, XP-V, which has been estimated to
comprise approximately 20% of XP patients (Moriwaki and
Kraemer, 2001), may have mild or severe clinical features,
including late onset of skin cancers, but rarely have
neurological abnormalities.
XP-V cells possess proficient nucleotide-excision repair
(Cleaver, 1972; Robbins et al., 1974, 1975; Broughton et al.,
2002; Tanioka et al., 2007), but display exaggerated delay in
recovery of replicative DNA synthesis in association with
defective post-replication repair (Lehmann et al., 1975; Itoh
et al., 1996). XP-V cells are hypersensitive to killing by UV
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irradiation in the presence of caffeine (Arlett et al., 1975;
Maher et al., 1976a; Broughton et al., 2002), are hypermu-
table after UV (Maher et al., 1976b; Wang et al., 1993), and
have post-UV plasmid hypermutability in a host cell
reactivation assay (Waters et al., 1993).
Extracts from XP-V cells are deficient in the ability to
bypass a thymine–thymine cyclobutane pyrimidine dimer in a
DNA replication assay (Svoboda et al., 1998). XP-V cells are
unable to synthesize intact daughter DNA strands on UV-
irradiated templates resulting from an inability to carry out
translesion synthesis, the synthesis of DNA directly past
damaged sites (Cordonnier et al., 1999). In 1999, the XPV
gene was cloned and found to be POLH (OMIM *603968)
(Johnson et al., 1999a; Masutani et al., 1999b), a human
homolog of the yeast RAD30 gene (McDonald et al., 1997).
This gene encodes DNA polymeraseZ (polZ) and is a
member of the Y-family of DNA polymerases (Ohmori
et al., 2001; Yang and Woodgate, 2007) related in structure
to each other, but unrelated to classical DNA polymerases.
The POLH gene is located on chromosome 6p21.1–6p12.3
spanning 40 kb and the calculated relative molecular mass
(Mr) of POLH is 78.4 kDa. The messenger RNA size is of
3,464 bp (GenBank reference number NM_006502), but the
size of the open reading frame is 2,139 bp as the first
methionine is located in exon 2 ( Johnson et al., 1999a;
Masutani et al., 1999b; Yuasa et al., 2000). The function of
polZ in the error-free bypass of UV-induced DNA lesions has
been well characterized ( Johnson et al., 1999b; Masutani
et al., 1999a, 2000). However, polZ can also function as a
highly mutagenic DNA polymerase when it replicates
undamaged DNA, and it has an important role in generating
immune diversity (Zeng et al., 2001; Yavuz et al., 2002).
Previous reports provided information about the molecular
defects in XP-V patients from the United States, Europe, and
Japan ( Johnson et al., 1999a; Masutani et al., 1999b; Itoh
et al., 2000a; Itoh and Linn, 2001; Broughton et al., 2002;
Gratchev et al., 2003; Tanioka et al., 2007). The causative
mutations reported in the POLH gene generally resulted in
severe truncations of the protein and are effectively null
alleles. We surveyed POLH mutations in XP-V patients from
different parts of the world in order to assess the origin of this
disorder and to attempt to correlate clinical features with
molecular defects. We studied cells from 15 XP-V patients in
10 families from the United States, the Cayman Islands,
Turkey, Israel, Germany, and Korea. We measured the polZ
protein levels and determined the causative mutations in the
POLH gene.
RESULTS
Characteristics of XP-V patients and cells
We evaluated 15 putative XP-V patients in 10 families from
the United States, the Cayman Islands, Turkey, Germany,
Israel, and Korea (Table 1; Figure 1). XP31BE, a 60-year-old
man in family A from the United States (Figure 1a), had
multiple basal cell carcinomas (BCCs), squamous cell
carcinomas (SCCs), and melanomas. As a teenager, the
Table 1. Clinical features and cellular assays in XP-V patients
Family Cell line Age/sex Race or nationality Cancer (type) Cellular assay
A XP31BE (GM13155) 60 years M Caucasian, USA Yes (BCC, SCC, MM) U, H
B XP1SE 66 years F Korean Yes (BCC, SCC) H
C XP71TMA*** (GM14875) 8 years M Turkish Yes (SCC, BCC) NT
C XP70TMA*** (GM15697) 17 years F Turkish Yes (SCC, BCC) U, H
C XP98TMA*** (GM15711) 26 years F Turkish Yes (SCC) NT
D XP91TMA**** (GM15700) 10 years M Turkish No NT
D XP92TMA**** (GM15713) d 22years M Turkish Yes (SCC) H
E XP38BE* (AG02592) 8 years M Cayman Island Yes (SCC conjunctiva) U, H
E XP39BE* (KR05822) 18 years F Cayman Island Yes (BCC) NT
F XP161BE** 46 years F Caucasian, USA Yes (BCC, MM) C
F XP164BE** 52 years F Caucasian, USA Yes (BCC, SCC, MM) C, H
G XP3GO 38 years M German Yes (BCC, SCC, MM) C, H
H XP139DC 19 years M USA Yes (BCC) U, C, H
I XP224BE (GM16818) 31 years F Caucasian, USA Yes (BCC, MM) H
J XP10TA 53 years F Iraqi–Israeli Yes (MM) H
BCC, cutaneous basal cell carcinoma; C, post-UV hypersensitivity after caffeine treatment; d, age at death; H, normal host cell reactivation; MM, cutaneous
melanoma; NT, not tested; SCC, cutaneous squamous cell carcinoma; U, normal post-UV unscheduled DNA synthesis; XP-V, xeroderma pigmentosum
variant.
*Siblings.
**Siblings.
***Siblings.
****Siblings.
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cancer-containing skin of his face was removed and replaced
with sun-protected skin from his trunk. This grafted skin has
remained cancer-free for more than 40 years to the present
time. Unscheduled DNA synthesis (UDS) of his cells was
normal. His fibroblasts had normal post-UV plasmid host cell
reactivation, at least 10 times higher than XP-C cells
(XP108DC) in this assay (Figure 2). These are typical features
of XP-V cells (Arlett et al., 1975; Maher et al., 1976a; Waters
et al., 1993; Itoh et al., 1996, 2000a; Broughton et al., 2002;
Friedberg et al., 2006). XP1SE, a 66-year-old Korean woman
in family B, had more than 10 BCCs and SCCs during the past
20 years (Kim and Chung, 2003). Her cells had normal host
cell reactivation (data not shown).
Family C from Turkey had three affected siblings,
XP71TMA, an 8-year-old boy with SCC and BCC (Figure 1b);
XP70TMA, a 17-year-old girl with SCC and BCC (Figure 1c);
and XP98TMA, a 26-year-old sister with SCC of her cheek
(Figure 1d). Their parents are distant cousins. The cultured
fibroblasts from patient XP70TMA showed normal post-UV
UDS and post-UV plasmid host cell reactivation (Figure 2).
XP91TMA, a 10-year-old boy in family D from Turkey was
cancer free (Figure 1e). His elder brother, XP92TMA, died at
22 years of age from an SCC originating on his lower lip
(Figure 1f). His cells had normal host cell reactivation
(Figure 2). Their parents are known to be related to each
other. However, families C and D lived in eastern Turkey, but
were not known to be related.
XP38BE in family E from the Cayman Islands had a
conjunctival SCC at the age of 8 years. UDS was 114% and
host cell reactivation was normal (Figure 2). XP39BE, his
affected sister, had seven BCCs by age 18. They are of mixed
English/African heritage. In family F, two adult sisters,
XP161BE (Figure 1g) and XP164BE (Figure 1h), from the
United States, had similar clinical features. Both had BCC and
melanoma, whereas XP164BE also had SCC. Their cultured
cells showed normal-to-mild UV sensitivity, with post-UV
hypersensitivity after caffeine treatment (Table 1). Cells
from XP164BE had normal post-UV host cell reactivation
(Figure 2).
XP3GO, a 38-year-old man in family G from Germany,
had 12 primary melanoma, 3 SCCs, and 7 BCCs in the past 16
years (Figure 1i). His cultured skin fibroblasts had post-UV
hypersensitivity after caffeine treatment (Table 1) and normal
host cell reactivation (Figure 2). XP139DC, a 19-year-old
man from the United States in family H, had a BCC. His cells
showed normal UDS and normal host cell reactivation (data
not shown). The cells had post-UV hypersensitivity to killing
after caffeine treatment (Table 1).
XP224BE, a 31-year-old Caucasian woman in family I
from the United States, had BCC and SCC (Figure 1j). Her
cultured cells had normal host cell reactivation (Figure 2).
XP10TA, a 53-year-old Iraqi–Israeli woman in family J, had
two melanomas. Her parents were first cousins. Her cells had
normal host cell reactivation (Figure 2).
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Figure 1. Clinical appearance of XP-V patients. Family A: (a) XP31BE, 60 year Caucasian man had full-thickness skin removed from his face as a teenager
because of multiple skin cancers. This skin was replaced with sun-protected skin from his abdomen and has been free of cancers ever since. He had BCC, SCC,
and melanomas on non-grafted skin of his head and upper extremities. Family C: (b) C-1, XP71TMA, 8-year-old Turkish boy, had SCC. (c) C-2, XP70TMA,
17-year-old sister of XP71TMA, had SCC and BCC. (d) C-3, XP98TMA, 26-year-old sister of XP71TMA, had a large SCC on her left cheek. Family D: (e) D-1,
XP91TMA, a 10-year-old Turkish man, had no skin cancers. (f) D-2, XP92TMA, brother of XP91TMA, died at age 22 years of metastasis of the SCC on his lip.
Family F: (g) F-1, XP161BE, a 46-year-old Caucasian woman with multiple skin BCCs and melanomas. (h) F-2, XP164BE, 52-year-old sister of XP161BE, had
multiple BCCs, SCCs, and melanomas. Family G: (i) XP3GO, a 30-year-old German man with multiple BCCs, SCCs, and melanomas. Family I: (j) XP224BE, a
31-year-old Caucasian woman, had multiple BCCs and melanomas.
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The patients we examined in families A, B, C, D, F, G, I,
and J had no XP-type neurological abnormalities (Rapin et al.,
2000) and none were reported for the other patients by the
referring doctors. These patients did not have loss of vision
due to corneal clouding. They showed a range of cutaneous
involvement and all showed freckling at an early age. The
patients in families C and D had marked progression of
pigmentary changes along with atrophy and telangiectasia.
However, in the others these changes remained limited
despite development of skin cancers. Their skin is similar in
appearance to chronic sun damage in fair-skinned individuals
in the general population.
Semi-quantification of polg protein expression
We used an immunoprecipitation (IP) procedure for detecting
polZ protein using monoclonal and polyclonal antibodies
(Thakur et al., 2001; Laposa et al., 2003; Tanioka et al., 2007)
in extracts from primary cells. As shown in Figure 3a, normal
fibroblast whole-cell extracts (lanes 1, 2, 6, 7, 12, and 16)
have a dark band of polZ protein, with an estimated size,
which is coincident with the expected size of 78.4 kDa. In
contrast, cell lines XP224BE (lane 5) and XP10TA (lane 11)
show faint bands, whereas the other XP-V cells (Figure 3a,
lanes 3, 4, 8, 9, 10, 13, 15, 17, and 18) show undetectable
levels of polZ protein. Similarly, protein extracted from
normal lymphoblastoid cells (AG10107 and AG10033)
showed an intense band at the expected size and lympho-
blastoid cells from XP31BE had an undetectable level of
polZ protein (data not shown). This assay demonstrates the
large difference in levels of polZ protein between normal and
XP-V cells (Table 2).
Mutation analysis
Sequencing of entire POLH coding region and exon/intron
junctions were carried out for exon 2 through exon 11. The
causative mutations were identified in all 10 cell lines. The
mutations and the predicted proteins encoded by the mutant
alleles are summarized in Table 2. Virtually all of the
mutations were located in regions that are likely to affect the
catalytic core of the enzyme. The exception was patient
XP139DC, who had a mutation in one allele of exon 11 of
POLH, encoding the C-terminus of polZ (see below). Of the
previously reported mutations in POLH that give rise to XP-V,
only 6 out of 60 (including those described here) have been
found in exon 11 (Johnson et al., 1999a; Masutani et al.,
1999b; Itoh et al., 2000b; Itoh and Linn, 2001; Broughton
et al., 2002; Gratchev et al., 2003; Tanioka et al., 2007),
suggesting that mutations in this region may give rise to mild
phenotypes that may be difficult to diagnose clinically as
XP-V.
POLH splice donor site mutations in XP31BE and XP1SE
Sequencing XP31BE genomic DNA from family A revealed a
mutation in the exon 6 splice donor site, G-to-C transversion
(c.764þ 1G4C) (Figure 4a). The sequence at this exon–intron
junction represents a strong donor site in the normal
sequence and the single base substitution in XP31BE reduced
its information content from 9.3 bits to 0.5 bits (Schneider,
1997a, b; Table S2). To confirm whether this splice donor site
mutation results in alteration of POLH mRNA splicing, we
performed reverse transcriptase-PCR (RT-PCR) surrounding
exon 6, using two primers, a forward primer (c504F) in exon
5 and a reverse primer (c892R) in exon 8/7 junction using
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Figure 2. Post-UV host cell reactivation assay showing normal DNA repair
in XP-V cells. UV-treated or control unirradiated luciferase containing
plasmid was transfected into cells from normal (AG5186) (light gray bar),
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Figure 3. Semi-quantitative estimation of polg and poli protein in XP and normal fibroblasts. Normal and putative XP-V cells were assayed by IP-Western
blotting of whole-cell extracts. (a) PolZ protein and (b) poli protein.
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RNA from the XP31BE and a control (Figure 4b). RT-PCR
showed that normal cells had a single band of the expected
size. In contrast, XP31BE had two shorter bands. Sequencing
of these two bands revealed two splice variants of POLH
mRNA. Type I splice form, with the greater expression, has a
deletion of the entire exon 6 (104 bp) (r.661_764del104)
(Table 2). This out-of-frame deletion is expected to produce a
221-amino-acid truncated protein (p.Val221Profs*2). Type II
splice form uses a cryptic splice donor site, 42 bp upstream
from the end of exon 6, which has an information content of
3.8 bits (Table S2). The resulting in-frame deletion
(r.723_764del42; p.ser242_Ile255del14) leads to shortening
of the polZ protein by 14 amino acids (Table 2). We
examined inheritance of the mutation in family A by using
PCR-restriction-fragment length polymorphism (RFLP) (Figure
4c). The G-to-C transversion creates a new DdeI restriction
site, which cuts the mutant genomic DNA into two fragments.
DdeI-treated DNA from the mother of XP31BE shows one
normal band as well as the shorter bands, indicating that she
is heterozygous for this mutation. However, DdeI-treated
DNA from the XP31BE patient shows only the shorter bands.
DdeI-treated DNA from the father does not show cutting by
this enzyme, indicating that the G-to-C mutation is absent.
But the genomic DNA sequence from the patient shows only
the mutated base (C) without the correct base (G), indicating
that he did not receive the correct base from either parent at
this site (Figure 4a). Thus, we assume that this region of the
DNA from his father is deleted. Hence, the XP31BE patient is
hemizygous for this splicing mutation (Table 2).
XP1SE in family B had a homozygous splice donor
mutation in exon 4 (c.490 G4T) (Table 2). This mutation
reduced the information content of the splice donor site from
5.4 to 2.1 bits (Table S2). We found two alternatively spliced
isoforms (r.401_490 del90 and r.490þ163) resulting in
Table 2. Polg protein and mutations in the XP-V cell lines examined
Polg mutations1
Allele 1 Allele 2
Family Cell line IP-western Genomic cDNA Type Amino acid
Size
(aa)2 Genomic cDNA Type Amino acid
Size
(aa)1
A XP31BE Absent g.24885 G4C
c.764+1G4C
1. r.661_764
del104
(del exon 6)*
Splicing p.Val221Profs*2 221 Hemizygous
2. r.723_764
del 42 (partial
del exon 6)
Splicing p.Ser242_Ile255
del 14
699
B XP1SE Absent g.11282 G4T
(exon 4)***
c.490 G4T
(exon 4)***
1.r.401_490
del90 (partial
del exon 4)
Splicing p.Gly134_Lys163
del30
683 Homozygous
2.r.490+163
(partial ins
intron 4)
Splicing p.Glu164Glyfs*29 191
C XP70TMA Absent g.11246 C4T c.454 C4T
(exon 4)
Nonsense p.Gln152* 151 Homozygous
D XP92TMA Absent g.11246 C4T c.454 C4T
(exon 4)
Nonsense p.Gln152* 151 Homozygous
E XP38BE Absent g.34350_
34351insG
c.1078dupG
(exon 10)*
Frameshift p.Asp360Gly
fs*32
390 Homozygous/
hemizygous
F XP164BE Absent g.34350_
34351insG
c.1078dupG
(exon 10)*
Frameshift p.Asp360Gly
fs*32
390 Homozygous
G XP3GO Absent g.24139_25203
del1065
c.661_764
del104
(del exon 6)*
Frameshift p.Val221Profs*2 221 Homozygous
H XP139DC Absent c.1075_1244
del170
(del exon 10)**
Frameshift p.Asn359Valfs*32 389 g.37914_37915
del2
c.1706_1707
del2
(exon 11)
Frameshift p.Thr569Argfs*10 577
I XP224BE Faint g.6811_6812insT c.149dupT
(exon 3)
Frameshift p.Ser51Glufs*3 52 g.21656 A4G c.658 A4G
(exon 5)
Missense p.Lys220Glu 713
J XP10TA Faint g.21520 G4T c.522 G4T
(exon 5)
Missense p.Trp174Cys 713 Homozygous
PolZ, DNA polymerase-Z; XP-V, xeroderma pigmentosum variant.
1GenBank reference sequence NC_000006.1 for genomic sequence and NM_006502.1 for cDNA.
2Predicted size.
*Mutation reported in Johnson (1999) Science: 285; 263 at cDNA level.
**Mutation reported in Broughton et al. (2002) at the cDNA level.
***Mutation reported in Tanioka et al. (2007).
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proteins of 683 (p.Gly134_Lys163del30) and 191 amino
acids (p.Glu164Glyfs*29), respectively, using cryptic donor
sites within exon 4 (6.1 bits) and within intron 4 (6.5 bits)
(Table S2). This same homozygous mutation was reported in
six XP-V patients from Japan (Tanioka et al., 2007). Many
Japanese XP-A patients have a splice mutation, which has
been identified as a founder mutation carried by about 1% of
the Japanese general population (Hirai et al., 2006). Possibly
this POLH splice mutation in Japan and Korea is also a
founder mutation.
Nonsense mutation in families C and D
XP70TMA in family C and XP92TMA in family D have the
same mutation in exon 4. This G-to-C transversion at position
454 (Table 2) resulted in a nonsense mutation (p.Gln152*).
The predicted protein size is 151 amino acids. This mutation
creates a DdeI restriction site (Figure 5). The digested DNA
from the mother of family C (XPH95TMA) shows three bands
indicating that she was heterozygous for this mutation.
The DNA from the affected siblings in both families
showed complete digestion, indicating that the mutation is
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Figure 4. Sequence analysis of family A. (a) Genomic DNA of XP31BE shows change of G to C at exon 6 splice donor site (arrows). There is a single curve in
the uncloned DNA, indicating homozygous or hemizygous mutation. (b) RT-PCR using RNA from XP31BE with forward primer C504F (in exon 5) and
reverse primer C892R (spanning the exon 8/7 junction) showed a single 388-bp band in normal cells and two bands (arrows) at 284 and 346 bp in XP31BE cells.
The diagram indicates deletion of the entire 104 bp of exon 6 in the type-I splice variant and partial deletion (42 bp) of exon 6 in the type-II splice variant.
(c) PCR-RFLP assay for family A. The G-to-C mutation creates a new DdeI restriction site. The gel shows genomic DNA from the father, XP31BE, mother,
and a normal donor. þ Indicates DdeI treatment. The arrows indicate 63 and 54-bp bands of digested DNA. * Indicates the normal-size band.
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the normal-size band.
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homozygous. This is consistent with the clinical history of
consanguinity in each of these families.
There is no history of a common relative linking family C
and family D. These families both live in eastern Turkey. Both
of these XP-V families have multiple affected children
(Figure 1, C-1, C-2, C-3, D-1, and D-2) and some of them
have developed skin cancer at an early age. An earlier study
of the inheritance of the XPC gene in a family from this region
of Turkey examined microsatellite markers and found a
genetic link to another XP-C family in Italy with a common
ancestor about 300–500 years ago (Gozukara et al., 2001).
Similar studies of microsatellites or single-nucleotide poly-
morphisms might indicate the extent of relationship between
these families.
Truncation in the catalytic domain of POLH
The cells from patients in families E and F had the same
mutation. Insertion of a single G at 1078 in exon 10 was
identified in XP38BE (c.1078_1079dupG) (Figure 6a) and
XP161BE (data not shown). This uncloned genomic DNA
sequence does not show double bands, thus indicating that
both alleles have the same insertion or that one allele has the
mutation and the other allele is absent. This frameshift
mutation codes for 31 unrelated amino acids before a
termination codon at codon 391 (p.Asp360Glyfs*32)
(Table 2). The mutation creates a new BslI site. Digestion of
DNA from XPH253BE, the mother of family E (Figure 6b),
produces three bands, indicating that she is heterozygous for
this mutation. DNA from the affected siblings XP38BE and
XP39BE is completely digested (Figure 6b), indicating that
they are homozygous or hemizygous for this mutation, as
suggested from the sequence tracing (Figure 6a). DNA from
the father was not available for testing. PCR-RFLP analysis of
DNA from family F (Figure 6c) shows complete digestion of
the DNA from both affected sisters XP164BE and XP161BE.
Digested DNA from both parents yields three bands,
indicating that they are heterozygous for this mutation. Thus,
we can conclude that the patients are homozygous (and not
hemizygous) for this mutation. As expected, the children of
patient XP161BE are heterozygous for this mutation (Figure
6c). Family E is from the Cayman Islands and family F from
the United States. We have no history of consanguinity
between these families. This mutation was also reported
(Johnson et al., 1999a) in XPPHBE, a 30-year-old Caucasian
man who has an affected brother, XP13BE (Robbins et al.,
1974; Moshell et al., 1981).
XP3GO cells in family G had a 1-kb deletion
(g.24139_25203del1065) in the genomic DNA that includes
exon 6 (Table 2). This homozygous deletion is predicted to
result in a truncated protein of 221 amino acids (p.Val221-
Profs*2). Mutated cDNA with this sequence was reported
previously (Johnson et al., 1999a) in cell line XP5MA from an
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+G1078
cag AAT
cag AAT
GAC
GGT ACAGGGA
AGG GTA
Intron 9 Exon 10
400-
300-
200-
100-
Bsl 1
Bsl 1
Bsl 1
XPH253BE
XP38BE
XP164BE
XP161BE
XP39BE
– – – – ++++
+G1078
Exon 10
353 bpWT
MT
105 bp 248 bp
NL
NL
Husband
Daughter Son Father Mother
+ + + + + + + +––––––––
_
200-
100-
Figure 6. Sequence analysis of families E and F. (a) Genomic DNA from XP38BE in family E shows an insertion of a G in exon 10. There is a single
sequence following the insertion indicating that the DNA is homozygous or hemizygous for this frameshift mutation. (b) PCR-RFLP assay of family E.
The insertion of G creates a new BsII site in the genomic DNA. Genomic DNA from a normal donor, patients XP38BE, XP39BE, and their mother, XPH253BE,
was run on a gel. þ Indicates BsII treatment. The 105 and 248-bp bands in the digested DNA are indicated by arrows. * Indicates the normal-size band.
(c) PCR-RFLP analysis for family F. Genomic DNA from XP164BE, XP161BE, the husband, son, daughter, mother, and father of XP161BE was run on a gel.
þ Indicates BsII treatment. The 105 and 248-bp bands in the digested DNA are indicated by arrows. * Indicates the normal size band.
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86-year-old woman from Germany with ‘‘pigmented xer-
odermoid’’ (Hofmann et al., 1978). The mutation in the
genomic DNA of XP5MA was not reported. Interestingly, the
deletion of exon 6 was also seen in the type-I splice isoform
in the cells from XP31BE who has a splice mutation (Table 2;
Figure 4b).
XP139DC cells in family H had two different frameshift
mutations (Table 2). Deletion of the 170 bases of exon 10
(c.1075_1244del170) resulted in an altered protein beginning
at Asn359 and terminating after 389 amino acids (p.Asn359-
Valfs*32). This same mutation was reported as homozygous
at the cDNA level in XP6VI and XP75VI cells (Broughton
et al., 2002). The other mutation in XP139DC cells was a 2 bp
deletion in exon 11 (c.1706_1707del2). This would result in a
truncated 577-amino-acid protein (p.Thr569Argfs*10).
XP224BE in family I is a compound heterozygote for a
frameshift mutation and a missense mutation (Table 2). One
allele has an insertion of a single T at nucleotide 149 in exon
3 (c.149_150dupT). This frameshift mutation creates a new
termination signal 3 codons downstream, resulting in a
truncated 52-amino-acid protein (p.ser51Glufs*3). This het-
erozygous mutation was identified in cells from her father
(XPH227BE) (data not shown). The þ T149 insertion inacti-
vates a BtsI restriction site. A PCR-RFLP assay using BtsI
confirmed that DNA from the patient, XP224BE, and her
father, XPH227BE, were heterozygous for this mutation, and
that DNA from her mother’s cells, XPH226BE, was not
digested, indicating a normal sequence (data not shown).
Missense mutations
The second allele of XP224BE carried a transition mutation of
A to G (c.658A4G) in exon 5 (Table 2). This missense
mutation changed lysine 220 (AAG) to glutamate (GAG)
(p.Lys220Glu), but preserved the size of the protein. This
heterozygous mutation was also present in cells from her
mother (XPH226BE) (data not shown). To determine if the
POLH c.658A4G mutation was a common polymorphism,
we screened DNA obtained from buccal swabs of 100
anonymous donors (Khan et al., 2000). DNA sequence
analysis showed the normal A/A genotype for all 100 donors,
indicating that the POLH c.658A4G mutation was not a
common polymorphism (data not shown).
The mutation of XP10TA in family J was homozygous for a
missense mutation in exon 5 based on the DNA sequence
analysis and the family history of consanguinity (Table 2).
This mutation (c.522 G4T), which changes tryptophan 174
to cystine (p.Trp174Cys), may affect protein conformation
because of the conversion from a hydrophobic amino acid to
a hydrophilic amino acid in the catalytic domain of POLH.
We determined that c.522G4T was not a common
polymorphism by screening 100 DNA samples from normal
donors (Khan et al., 2000) using PCR-RFLP analysis with
BsmAI. All of the donors’ samples had the restriction pattern
of the normal G/G genotype (data not shown).
POLH mRNA in XP-V cells
Western blotting (Figure 3) and sequence analysis (Table 2)
indicated that polZ protein was not detectable in the mutant
cells that yielded premature terminations, and a faint band
could be seen in the mutants that had missense mutations.
One mechanism for the observed large reduction in polZ
protein would be nonsense mediated message decay
(Kuzmiak and Maquat, 2006). Nonsense-mediated message
decay has been observed in cells from XPC patients who have
mutations leading to premature stop codons (Khan et al.,
2006). We measured POLH mRNA levels (Table 3; Table S1)
in XP-V cell lines that had no detectible polZ protein
(Figure 3) resulting from a splice site mutation (XP31BE), a
frameshift mutation (XP38BE), or a nonsense mutation
(XP70TMA) (Table 2). Three normal fibroblast strains had a
mean of 77.2 fg of full-length message (exon 1/exon 2
boundary primer), 81.9 fg (exon 2/exon 3 boundary primer),
and 3 fg of POLH mRNA (exon 2-skipping primers) (Table 3).
The cell strains with splicing and frameshift mutations had
normal levels of POLH mRNA (Table 3), demonstrating
absence of nonsense-mediated message decay in these cells.
The cell strain with a nonsense mutation (XP70TMA) had
POLH mRNA levels that were about half of normal (Table 3),
demonstrating nonsense-mediated message decay in these
cells. All of the cell strains had normal levels of skipping of
exon 2 in POLH mRNA.
Poli in XP-V cells
DNA polymerasei (poli) is another Y-family DNA polymerase
(Woodgate, 1999; Ohmori et al., 2001; Kannouche et al.,
2003) that was recently identified as playing a role in
carcinogenesis in cells lacking polZ (Wang et al., 2007). We
measured the level of poli protein in XP-V cells with
undetectable or with very low levels of polZ (Figure 3b).
All of the cells examined had levels of poli protein in the
normal range (Figure 3b, and data not shown).
DISCUSSION
Laboratory identification of XP-V cells
XP-V classically has been defined by the combination of the
clinical features of XP with normal post-UV cell survival that
is reduced by caffeine, normal post-UV UDS and reduced
post-UV DNA synthesis (Itoh et al., 1996). These conventional
laboratory examinations separate XP-V from normal cells, but
they cannot identify the molecular defect in XP-V cells. The
identification of the POLH gene has greatly facilitated
molecular diagnosis of XP-V. IP-western blotting was able to
detect POLH protein in nuclear extracts from simian virus-
transformed cells (Thakur et al., 2001; Laposa et al., 2003). In
this procedure, POLH protein from SV-transformed normal
cells showed a dark band at 78 kDa, whereas POLH protein in
XP-V SV-transformed cells (XP30RO) was not detected. The
monoclonal antibody for polZ recognized the 300 amino
acids at the C-terminal end of polZ protein. XP30RO cells,
with a 13-base deletion in exon 2, generate a severely
truncated protein, which deletes the recognition site of the
antibody. We have simplified this assay permitting use of
whole-cell extracts, simplified IP, and measurement of protein
concentration by a standard protocol. The simplified method
detects polZ levels in primary fibroblasts (Figure 3; Tanioka
et al., 2007) and lymphoblastoid cells.
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Undetectable polg protein: nonsense-mediated message decay
and post-translational degradation
One mechanism for the observed large reduction in polZ
protein would be nonsense-mediated message decay (Kuz-
miak and Maquat, 2006). For example, nonsense-mediated
message decay has been observed in cells from XP-C patients
who have mutations leading to premature stop codons (Khan
et al., 2006). An XP-V cell strain (XP70TMA) with a nonsense
mutation in the POLH gene (Table 2) had no detectable polZ
protein levels (Figure 3) and showed about 50% of normal
POLH mRNA levels (Table 3). This reduction in mRNA level
may be due to nonsense-mediated message decay; however,
the level of reduction of mRNA is less than seen in XP-C cells
with nonsense mutations (reduced too25% of normal) (Khan
et al., 2006). Northern blots from XP-V cells showed different
levels of poly(A)þ RNA ranging from undetectable to normal
levels in different cells with nonsense or frameshift mutations
(Masutani et al., 1999b). We found normal levels of POLH
mRNA in XP-V cell strains with no detectable polZ protein
and splice (XP31BE) or frameshift (XP38BE) mutations
(Table 3). Thus, these cells have no evidence of nonsense-
mediated message decay. The low polZ protein levels may be
caused by increased proteolysis mediated via ubiquitin
binding, as demonstrated in studies of polZ (Bienko et al.,
2005) or its yeast homologue, RAD30 (Skoneczna et al., 2007).
Trace protein levels: missense mutations with alteration of RNA
processing and protein degradation
XP10TA and XP224BE(2) have missense mutations in the
catalytic domain, and western blotting showed faint bands of
Table 3. Polg mRNA levels in XP-V cell lines
POLH WT (exons 1–2/2)1 POLH WT (exon 2/3–2)1 POLH-skipping exon 2 (exon 1/3–1)1
Cell line SQ SQ mean SQ SQ mean SQ SQ mean
XP-V
XP31BE 81.5 80.8 2.5
76.0 78.6 102% 103 92.9 113% 3.6 3.3 109%
78.3 94.8 3.8
XP38BE 92.9 85.5 3.5
81.4 85.1 110% 88.7 91.3 111% 3.8 3.7 122%
80.9 99.6 3.7
XP70TMA 39.4 44.1 4.5
37.8 37.7 49% 41.7 42.3 52% 3.8 4.1 137%
36.0 41.2 4.1
XP-V mean 67.1 XP-V mean 75.5 XP-V mean 3.7
Normals
AG5186 91.7 104 2.3
92.5 90.9 89.2 95.0 3.9 3.3
88.6 91.7 3.6
AG13153 77.4 93.3 2.9
103 89.7 94.7 92.0 4.9 3.8
88.8 88.0 3.7
AG13145 49.2 52.2 2.0
50.1 51.0 64.3 58.7 1.7 1.9
53.6 59.6 2.1
Normal mean 77.2 100% Normal mean 81.9 100% Normal mean 3.0 100%
PolZ, DNA polymeraseZ; WT, wild type; XP-V, xeroderma pigmentosum variant.
1Full-length (FL) and major alternative spliced (del ex 2) POLH mRNA levels (fg of plasmid DNA) in fibroblasts measured by quantitative real-time reverse
transcriptase-PCR.
www.jidonline.org 2063
H Inui et al.
Xeroderma Pigmentosum Variants
polZ protein (Table 2; Figure 3a). XP10TA has a homozygous
base substitution mutation in exon 5 that results in a missense
mutation Trp174Cys. The c.522 G4T mutation increases the
strength of a cryptic RNA splice acceptor (Schneider,
1997a, b) within exon 5 from 8.8 to 10.2 bits (data not
shown). This mutation within an exon may result in altered
RNA splicing as reported in cells from patients with isovaleric
acidemia (Vockley et al., 2000), with accompanying low
levels of protein. Similarly, the heterozygous c.658 A4G
base substitution mutation in exon 5 in XP224BE reduces the
information content of the donor from 7.8 to 6.8 bits (Table 3,
and data not shown), possibly reducing the extent of normal
splicing leading to low levels of polymeraseZ protein.
Alternatively, the missense mutation may alter the stability
of the protein as described for XPC (Yasuda et al., 2007) or for
Escherichia coli umuC, the bacterial equivalent of polZ
(Woodgate et al., 1994). The two missense mutations,
tryptophan (hydrophobic amino acid) 174 to cysteine
(hydrophilic amino acid) in XP10TA and lysine (basic amino
acid) 220 to glutamate (acidic amino acid) in XP224BE, may
influence the polZ protein conformation, resulting in
instability or structure change at the epitope of antibody
binding. One cell line, XP11BR, with a missense mutation in
the catalytic domain, has been reported to be defective in
translesion synthesis activity (Broughton et al., 2002). This
glycine 263-to-valine alteration leads to the conversion from
a hydrophilic amino acid to a hydrophobic amino acid.
Mutation spectrum and predicted POLH protein function
Following results of IP-western blotting, we sequenced eight
cell lines, which have no band of polZ protein and two cell
lines with a faint band. We found 10 different mutations in 10
patients. These mutations were classified as splicing, frame-
shift, nonsense, and missense (Table 2). The functional
structure of pol-Z protein has been elucidated (Figure 7;
Johnson et al., 1999a; Masutani et al., 1999b; Yamada et al.,
2000; Kannouche et al., 2001, 2003; Ling et al., 2001, 2003;
Broughton et al., 2002; Bomar et al., 2007; Yang and
Woodgate, 2007). The N-terminal 400 amino acids are highly
conserved in the Y-family polymerases (Boudsocq et al.,
2002). The polymerase activities of polZ reside entirely in the
first 511 amino acids of the 713-amino-acid protein (Masutani
et al., 1999a). The C-terminal 200-amino-acid region does not
have polymerase function, but contains a bipartate nuclear
localization signal between residues 682–698 and the C-
terminal. The C-terminal 120 amino acids of polZ are
sufficient for nuclear localization, and for localization into
foci (Kannouche et al., 2001). Cell-free extracts from XP-V
with severe truncation in the catalytic domain were shown to
be defective in translesion synthesis activity. This suggests that
mutant alleles with truncations between 52 and 390 amino
acids in our patients’ cells (XP31BE, XP3GO, XP38BE,
XP161BE, XP70TMA, XP92TMA, XP224BE(1), and XP1SE
variant II) would have defective polymerase activity.
Splice variant II of XP31BE has a 13-amino-acid in-frame
deletion in exon 6. XP3DU with in-frame deletion in exon 3
also has defective bypass ability in a translesion synthesis
assay (Broughton et al., 2002). This suggests that mutations
found in the patients’ cell lines with undetectable or faint
bands of polZ protein in western blotting are causative for
XP-V.
Splicing abnormalities
Information theory is an important tool to rank normal and
mutant splice junctions, and most splice junctions that are
fully functional have an information content of at least 2.4
bits (Schneider, 1997a, 1997b; Rogan et al., 1998). Splice-
site mutations may result in exon skipping, activation of
cryptic splice sites, creation of a pseudo-exon within intron,
or intron retention. The splice donor at exon 6 in normal
sequence has an information content of 9.3 bits (Table S2).
The exon 6 splice donor site mutation in XP31BE inactivates
the normal splice donor, resulting in two splice variants, one
of which results from skipping of exon 6 and the other from
activation of a cryptic splice site in exon 6 (Figures 4 and 7).
Another XP-V cell (XP1RO) had a splice acceptor site
mutation in exon 2 (Masutani et al., 1999b). This mutation
also reduced information content at the splice acceptor from
3.4 to o0 bits, and led to skipping of exon 2. XP1SE has a
mutation within exon 4, which reduces the splice donor site
information from 5.4 bits to 2.1 bits.
Origin, inheritance, and clinical features of XP-V mutations in
different parts of the world
Some DNA-repair genes also function as basal transcription
factors and are thus essential for survival. Complete
inactivation of both alleles of these genes is not compatible
with life. Thus, mutations in affected patients must preserve
some genetic activity and hence only a limited set of
mutations would be observed in at least one allele. An
example of this is the XPD gene where unrelated patients
from many different countries have mutations at the same site
(R683W) (Taylor et al., 1997; Lehmann, 2003; Friedberg
et al., 2006). This mutation has been shown to retain some
activity (Dubaele et al., 2003). In contrast, the XPC gene is
not essential for life and can be completely inactivated with
undetectable levels of XPC protein (Khan et al., 2006). In the
XPC gene, many different mutations have been found without
an accumulation at one site (Chavanne et al., 2000;
Gozukara et al., 2001; Friedberg et al., 2006; Khan et al.,
2006).
The XP-V gene appears to be closer to the model of a non-
essential gene, with no one site having a preponderance of
mutations (Johnson et al., 1999a; Broughton et al., 2002;
Tanioka et al., 2007) and undetectable levels of polZ protein
(Figure 3). We found 10 mutations in POLH in 10 families.
Two families from Turkey (families C and D) had the same
homozygous nonsense mutation, whereas two families from
North America (families E and F) had the same homozygous
frameshift mutation. A patient from Korea had the same
probable founder mutation as that in Japanese XP-V patients
(Tanioka et al., 2007). The other five families had seven
different mutations. These probably arose independently.
The 15 XP-V patients we studied had a range of clinical
features (Table 1). None had XP related neurological
abnormalities (Rapin et al., 2000; Kraemer et al., 2007) or
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loss of vision due to corneal clouding. They all developed
freckles at an early age. In some of the patients, this did not
progress (for example, XP224BE and XP10TA) and their skin
looked similar to that of chronic sun damage in fair-skinned
individuals in the general population. While in others, for
example, in patients from Turkey (families C and D) (Figure 1),
the skin changes resulted in extensive cutaneous pigmenta-
tion and atrophy. All of the patients, except for two of the
youngest, had skin cancer and six had melanoma. This is
similar to the average age of reported skin cancer in more
than 800 XP patients of less than 10 years (Kraemer et al.,
1987, 1994). The group includes four (27%) XP-V patients
older than 45 years (Table 1). This is a relatively old age for
XP patients compared with the 5% of 785 reported XP
patients who were older than 45 years (Kraemer et al., 1987),
and may reflect a tendency of XP-V patients to live longer
than XP patients with defects in nucleotide-excision repair
genes. However, one XP-V patient, XP92TMA (Table 1;
Figure 1, D-2) died of metastatic SCC of his lip at 22 years of
age. Our first XP-V patient, XP4BE, had ocular involvement,
extensive cutaneous changes, more than 100 skin cancers, and
died at 27 years of metastatic melanoma (Robbins et al.,
1974, 1975).
A correlation between the clinical features and the
different POLH mutations is not clear (see also Tanioka
et al., 2007). Cells from the two patients with missense
mutations (XP24BE and XP10TA) showed trace polZ protein
on the western blots (Figure 3), and were from adults without
marked progression of their pigmentary abnormalities. The
patients with extensive cutaneous pigmentation and atrophy
(families C and D) had a homozygous nonsense mutation that
resulted in no detectible polZ protein (Figure 3). However,
other patients with absent polZ protein did not show these
extensive cutaneous changes.
XP and poli protein
We also examined the level of polZ protein in 16 cell
strains from other suspected UV-sensitive, cancer-prone XP-V
patients who were referred to the authors. We found them to
have normal post-UV cell survival, host cell reactivation, or
Genomic DNA
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XP38BE,
XP164BE
XP224BE (1)
XP224BE (2)
XP70TMA
XP92TMA
XP92TMA
XP70TMA,
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XP1SE
XP1SE
Splice variant I
Splice variant II
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XP3GO
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XP10TA
XP31BE
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XP139DC (1)
XP139DC (1)
XP139DC (2)
XP139DC (2)
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XP164DC
mRNA
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628–662
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511400
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683 aa
221 aa
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c.1078dupG, p.Asp360GLyfs*32
c.1075_1244del170, p.Asn359Valfs*32
c.1706_1707del2, p.Thr569Argfs*10
151 aa
221 aa
52 aa
c.764+1G>C, r.661_764del104, p.Val221Profs*2
c.490G>T, r.401_490del90, p.Gly134_Lys163del30
c.490G>T, r.490+163, p.Glu164Glyfs*29
c.454G>T, p. Gln152*
g.24139_25203del1065, c.661_764del104, p.val221Profs*2
c.764+1G>C, r.723_764del42, p.Ser242_IIe255 del14
c.149dupT, p.Ser51Glufs*3
c.658A>G, p.Lys220Glu
c.522G>T, p.Trp174CysLys220Glu
Trp174Cys
Figure 7. Mutation spectrum and predicted proteins in XP-V cells. The top line shows the 11 exons of POLH genomic sequence on chromosome 6 as
filled rectangles. The location of frameshift, nonsense, and missense mutations in each allele for the cells studied is shown above the line and the splice site
mutations are shown below the line. The second line shows the mRNA with the ATG initiation codon in exon 2 and the TAG stop codon in exon 11. The
713-amino-acid pol-Z protein is shown in the third line. The N-terminal 400 amino acids are highly conserved in Y-family polymerases, and contain the
catalytic domain of the polymerase. There is a nuclear localization signal located at amino acids 682–698 (NLS). The C-terminal region from amino
acids 628–662 contains a C2H2 zinc finger that is involved in DNA-binding ubiquitin. A PCNA-binding site is located at the extreme C-terminus of the protein.
The bottom portion of the figure shows the predicted size of the protein from each allele or splice variant form from the XP-V patients and the description
of the mutation at the cDNA and protein level. PCNA, proliferating-cell nuclear antigen.
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DNA repair (data not shown). However, unlike true XP-V
cells, these cells had normal levels of polZ protein and we
were unable to detect any mutations in POLH (data not
shown). We therefore considered the possibility that these
clinical phenotypes may have arisen because of mutations in
another polymerase involved in the translesion synthesis of UV
photoproducts. A good candidate enzyme appeared to be poli,
which is a paralog of polZ (Ohmori et al., 2001). Poli has also
been shown to physically interact with polZ, and both
polymerases colocalize to sites of UV-induced DNA damage
(Kannouche et al., 2002). Furthermore, poli can bypass
cyclobutane dimers in vitro (Vaisman et al., 2003; Frank and
Woodgate, 2007) and mice lacking poli exhibit mild sensitivity
to UV-light (Dumstorf et al., 2006). We therefore measured the
level of poli protein in these cells, as well as sequenced the
entire POLI gene. However, all cells exhibited normal levels of
poli protein and did not contain any mutations in POLI
(data not shown). The molecular defects causing the pheno-
type resembling XP-V in these cells therefore remain to be
determined.
MATERIALS AND METHODS
Patients and cells
Patients were examined in accordance with the Institutional Review
Boards at their institutions (National Institutes of Health, Bethesda,
MD; Yu¨zu¨ncu¨ Yil University Medical School, Van, Turkey; Wuerz-
burg University, Wurzburg, Germany; Armed Forces Institute of
Pathology, Washington, DC; Yonsei University College of Medicine,
Seoul, Korea; and Tel Aviv University, Tel Aviv, Israel) or their cells
were obtained from the Human Genetic Mutant Cell Repository,
Camden, NJ. The studies followed the Declaration of Helsinki
Principles and patients gave informed consent for these studies. The
cell lines examined in this study are listed in Table 1. Patients’ skin
primary fibroblasts (XP31BE (GM13155), XP38BE (AG02592),
XP70TMA (GM14873), XP92TMA (GM15713), XP224BE
(GM16818), and lymphoblastoid cell lines (XP31BE (GM13154)
and normals (AG10107 and AG10033)) were obtained from the
Human Genetic Mutant Cell Repository, Camden, NJ. XP10TA cells
were established at Tel Aviv University. XP161BE, XP164BE,
XP139DC, and the XP-C strain, XP108DC, were supplied by the
Department of Environmental and Toxicologic Pathology, Armed
Forces Institute of Pathology, Washington, DC. XP3GO primary
fibroblasts were established at the Department of Dermatology,
Georg-August-University, Goettingen, Germany. XP1SE was ob-
tained from Department of Dermatology and Cutaneous Biology
Research Institute, Yonsei University College of Medicine, Seoul,
Korea. Normal skin primary fibroblasts (AG4659, AG5186,
AG13153, and AG13145) were obtained from the Human Aging
Cell Repository, Camden, NJ. Fibroblast cell lines were grown in
DMEM (Invitrogen, Grand Island, NY) containing 4mM glutamine
and 10% fetal calf serum, as previously described (Khan et al.,
2004).
Host cell reactivation assay
To screen the UV sensitivity of the cells, we performed post-UV host
cell reactivation assay as described previously (Emmert et al., 2002).
The pCMVLuc reporter gene plasmid (a generous gift from M
Hedayati and L Grossman, John Hopkins University, Baltimore, MD)
was used to measure post-UV host cell reactivation. A 200-ng weight
of CsCl-purified pCMVLuc, either 1,000 Jm2 UV-irradiated or
unirradiated, was transfected into 1.5 105 fibroblast cells per well
using 4 ml of Lipofectamine (Invitrogen) in a total 1ml of OPTI-MEM
medium (Invitrogen) for 5 hours. After 48 hours of incubation,
luciferase activity was measured with a luminometer (Monolight
2010; Analytical Luminescence Laboratory, San Diego, CA) using
luciferase assay reagent (Promega, Madison, WI) according to the
manufacturer’s protocol. Relative luciferase activities are presented
as a percentage of activities obtained with UV-irradiated versus
unirradiated control plasmids.
Semi-quantitative estimation of polg and poli protein expression
PolZ and poli protein levels were assessed by IP followed by
western blotting as described previously (Thakur et al., 2001;
Kannouche et al., 2003; Laposa et al., 2003; Tanioka et al.,
2007). Poli protein was detected using a rabbit polyclonal
antibody directed against a keyhole limpet hemocyanin-conjugated
peptide corresponding to the extreme C-terminal 15 amino-
acid residues (AEWKRTGSDFHIGHK) of poli (Kannouche et al.,
2002).
PCR amplification, sequencing of POLH and POLI, and
measurement of POLH mRNA
DNA was isolated using DNAzol reagent as per vendor’s
protocol (Invitrogen). Total cytoplasmic RNA was isolated from cells
by the RNA aqueous small-scale phenol-free total RNA isolation kit
(Ambion, Austin, TX) according to the vendor’s protocol. To sequence
the entire coding region and exon–intron junction sites of
POLH and POLI genes, each exon and the entire coding region were
amplified using intronic and exonic primers (Table S1). The primers
were designed on the basis of the GenBank reference sequences
(accession no. NC_000006 for POLH genomic sequence;
NM_006502 for POLH cDNA sequence; and NC_000018 for
POLI genomic sequence). RT-PCR amplification of the entire
coding region of POLH was performed using primers S0
(GATCCCTTCTCGGTTTCTCC) and AS24 (ATCCTACAGG-
CAAGCCTGAG) (Masutani et al., 1999b), with two PCR involving
denaturing at 94 1C for 1minute, 35 cycles of denaturing at 94 1C for
20 seconds, and annealing/extension at 70 1C for 3minutes,
followed by extension at 70 1C for 3minutes. PCR products were
sequenced by using the Thermo Sequenase II dye-terminator cycle
sequencing Premix Kit (Amersham Pharmacia, Piscataway, NJ). POLI
sequence analysis was performed similarly as described for POLH.
Real-time quantitative RT-PCR for measurement of POLH mRNA
was performed with pairs of primers, where one primer
spanned an exon–exon boundary as described by Khan et al.
(2002) (2006) (Table S1).
Mutations were described according to the recommendations
of the Human Genome Variation Society (den Dunnen and
Antonarakis, 2000) (http://www.hgvs.org/mutnomen/) and the
nomenclature was checked using the mutalyzer website http://
www.lovd.nl/mutalyzer/1.0.1/.
DNA sequence information analysis
The sequences of normal splice donor and acceptor sites of each
exon and all of the sequences with mutations we identified were
scanned with the donor and acceptor individual information weight
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matrices (Schneider, 1997a, b). This analysis can be performed on a
web server, https://splice.cmh.edu/. The normal sequences of splice
donor and acceptor sites of each exon and information contents are
calculated and listed in Table S2.
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